Cited by 440Atherosclerosis and Cardiovascular DiseasesCardiovascular, Neuropeptides, and Oxidative Stress ResearchCerebrovascular and Carotid Artery Diseases

Extensive Proliferation of a Subset of Differentiated, yet Plastic, Medial Vascular Smooth Muscle Cells Contributes to Neointimal Formation in Mouse Injury and Atherosclerosis Models

Open access
Chappell, Joel, Harman, Jennifer L., Narasimhan, Vagheesh M., Yu, Haixiang, Foote, Kirsty, Simons, Benjamin D., Bennett, Martin R., Jørgensen, Helle F.·2016·Circulation Research

Abstract

Rationale: Vascular smooth muscle cell (VSMC) accumulation is a hallmark of atherosclerosis and vascular injury. However, fundamental aspects of proliferation and the phenotypic changes within individual VSMCs, which underlie vascular disease, remain unresolved. In particular, it is not known whether all VSMCs proliferate and display plasticity or whether individual cells can switch to multiple phenotypes. Objective: To assess whether proliferation and plasticity in disease is a general characteristic of VSMCs or a feature of a subset of cells. Methods and Results: Using multicolor lineage labeling, we demonstrate that VSMCs in injury-induced neointimal lesions and in atherosclerotic plaques are oligoclonal, derived from few expanding cells. Lineage tracing also revealed that the progeny of individual VSMCs contributes to both alpha smooth muscle actin (aSma)–positive fibrous cap and Mac3-expressing macrophage-like plaque core cells. Costaining for phenotypic markers further identified a double-positive aSma+ Mac3+ cell population, which is specific to VSMC-derived plaque cells. In contrast, VSMC-derived cells generating the neointima after vascular injury generally retained the expression of VSMC markers and the upregulation of Mac3 was less pronounced. Monochromatic regions in atherosclerotic plaques and injury-induced neointima did not contain VSMC-derived cells expressing a different fluorescent reporter protein, suggesting that proliferation-independent VSMC migration does not make a major contribution to VSMC accumulation in vascular disease. Conclusions: We demonstrate that extensive proliferation of a low proportion of highly plastic VSMCs results in the observed VSMC accumulation after injury and in atherosclerotic plaques. Therapeutic targeting of these hyperproliferating VSMCs might effectively reduce vascular disease without affecting vascular integrity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circresaha.116.309799

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lineage tracing studies have unambiguously demonstrated that VSMCs contribute substantially to plaque formation in murine models of atherosclerosis, generating 30-70% of all plaque cells.

    “Lineage tracing studies have unambiguously demonstrated that VSMCs contribute substantially to plaque formation in murine models of atherosclerosis, generating 30-70% of all plaque cells 11,18-20,22,23 .”

    From Vascular smooth muscle cells in atherosclerosis (2019) · cites this paper as [20]

  • Within plaques a large proportion of reporter-expressing VSMC-derived cells do not have detectable levels of the contractile smooth muscle cell marker αSMA.

    “Within plaques a large proportion of reporter-expressing VSMC-derived cells do not have detectable levels of the contractile smooth muscle cell marker α SMA 11,20 .”

    From Vascular smooth muscle cells in atherosclerosis (2019) · cites this paper as [20]

  • Some plaque reporter-expressing cells were positive for Mac-3, Lgals3 and CD68, markers previously used to study macrophages in atherosclerosis.

    “Instead, some plaque reporter-expressing cells were positive for Mac-3 20 , Lgals3 11 and CD68 17 - markers that have been previously used to study macrophages in atherosclerosis.”

    From Vascular smooth muscle cells in atherosclerosis (2019) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [29]Andreassi MG Botto N Colombo MG Biagini A Clerico A Genetic instability and atherosclerosis: can somatic mutations account for the development of cardiovascular diseases? Environ Mol Mutagen 2000 35 265 269 doi: 10.1002/1098-2280 10861945 · DOI

Cited by

Sorted by citations

Authors
Chappell, J., Harman, J. L., Narasimhan, V. M., Yu, H., Foote, K., Simons, B. D., Bennett, M. R., & Jørgensen, H. F.
Affiliations
  • Wellcome/MRC Cambridge Stem Cell Institute (GB)
  • From the Cardiovascular Medicine Division, Department of Medicine (J.C., J.L.H., H.Y., K.F., M.R.B., H.F.J.), Cavendish Laboratory, Department of Physics (B.D.S.), The Wellcome Trust/Cancer Research UK Gurdon Institute (B.D.S.), and Wellcome Trust-Medical Research Council Stem Cell Institute (B.D.S.), University of Cambridge, United Kingdom; and The Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom (V.M.N.).
Corresponding author
Jørgensen, Helle F.
Venue
Circulation Research
Published
2016-12-09
Volume
119
Issue
12
Pages
1313-1323
ISSN
  • 0009-7330 (ISSN-L)
  • 1524-4571
OpenAlex
W2525459565
Cited by
437
References
32
Citations by year
2026: 39 · 2025: 38 · 2024: 45 · 2023: 56 · 2022: 62 · 2021: 62 · 2020: 39 · 2019: 45 · 2018: 29 · 2017: 17 · 2016: 3
FWCI
18.96
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Circulation Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Wellcome Trust (098357/Z/12/Z, 100574/Z/12/Z)
  • British Heart Foundation (PG/13/25/30014, PG/16/11/32021, PG/12/86/29930, RM/13/3/30159, RG/13/14/30314, FS/15/38/31516, RE/13/6/30180)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cerebrovascular and Carotid Artery Diseases
Keywords
vascular smooth muscle cells, vascular smooth muscle cell proliferation, phenotypic plasticity, intimal hyperplasia, atherosclerosis, atherosclerotic plaque, lineage tracing, alpha-smooth muscle actin, VSMC migration, vascular injury
MeSH terms
Animals, Disease Models, Animal, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Muscle, Smooth, Vascular, Mice, Knockout, Myocytes, Smooth Muscle, Cell Proliferation, Atherosclerosis, Mice, Vascular System Injuries, Neointima

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review